DAT Protein

DAT Protein

Introduction

Dat Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Dopamine Transporter [@zetterstrm2021]

<div class="infobox infobox-protein"> [@varrone2012]
<div class="infobox-header">DAT Protein</div> [@shin2020]
<div class="infobox-content">
| Property | Value |
|---------|-------|
| Protein Name | Dopamine Transporter (DAT) |
| Gene | SLC6A3 |
| UniProt | Q01959 |
| PDB | 4MDS, 5JU6 |
| Molecular Weight | ~79 kDa (glycosylated) |
| Subcellular Localization | Plasma membrane, presynaptic terminals |
| Protein Family | Na+/Cl- dependent neurotransmitter transporter (SLC6) |
</div>
</div>

Overview

The dopamine transporter (DAT) is a membrane protein that terminates dopaminergic neurotransmission by reuptaking dopamine from the synaptic cleft back into presynaptic [neurons](/entities/neurons). It is essential for maintaining dopamine homeostasis and is a critical player in Parkinson's disease and other dopamine-related disorders.

Structure

DAT belongs to the SLC6 family of Na+/Cl- dependent transporters:

• 12 Transmembrane Domains: Characteristic of neurotransmitter transporters
• Intracellular N- and C-termini: Important for regulation
• Glycosylated Extracellular Loops: 2-4 glycosylation sites
• Substrate Binding Site: Central to the transport mechanism

Normal Function

DAT functions in:

...

DAT Protein

Introduction

Dat Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Dopamine Transporter [@zetterstrm2021]

<div class="infobox infobox-protein"> [@varrone2012]
<div class="infobox-header">DAT Protein</div> [@shin2020]
<div class="infobox-content">
| Property | Value |
|---------|-------|
| Protein Name | Dopamine Transporter (DAT) |
| Gene | SLC6A3 |
| UniProt | Q01959 |
| PDB | 4MDS, 5JU6 |
| Molecular Weight | ~79 kDa (glycosylated) |
| Subcellular Localization | Plasma membrane, presynaptic terminals |
| Protein Family | Na+/Cl- dependent neurotransmitter transporter (SLC6) |
</div>
</div>

Overview

The dopamine transporter (DAT) is a membrane protein that terminates dopaminergic neurotransmission by reuptaking dopamine from the synaptic cleft back into presynaptic [neurons](/entities/neurons). It is essential for maintaining dopamine homeostasis and is a critical player in Parkinson's disease and other dopamine-related disorders.

Structure

DAT belongs to the SLC6 family of Na+/Cl- dependent transporters:

• 12 Transmembrane Domains: Characteristic of neurotransmitter transporters
• Intracellular N- and C-termini: Important for regulation
• Glycosylated Extracellular Loops: 2-4 glycosylation sites
• Substrate Binding Site: Central to the transport mechanism

Normal Function

DAT functions in:

• Dopamine Reuptake: Primary mechanism for synaptic dopamine clearance
• Ion Coupling: Uses Na+ and Cl- gradients (2 Na+:1 dopamine:1 Cl-)
• Neuroprotection: Prevents extracellular dopamine accumulation
• Regulation: Modulated by kinases, phosphatases, and protein interactions

Role in Disease

Parkinson's Disease

• DAT Imaging: DaTscan uses I-123 ioflupane to visualize DAT binding
• Presynaptic Marker: Reduced DAT correlates with dopaminergic neuron loss
• Early Detection: DAT imaging can detect presynaptic deficits pre-symptomatically

ADHD

• Methylphenidate: DAT inhibitor used to treat ADHD
• Genetic Variants: 40-bp VNTR affects DAT expression and ADHD risk

Psychostimulant Addiction

• Cocaine: DAT inhibitor - blocks dopamine reuptake
• Amphetamines: Substrate for DAT - reverse transport

Therapeutic Targeting

DAT Inhibitors

| Drug | Use | Mechanism |
|------|-----|-----------|
| Methylphenidate | ADHD | DAT blockade |
| Cocaine | Abuse | DAT blockade |
| Amphetamine | ADHD, Narcolepsy | Reverse transport |

Imaging Agents

• DaTscan (I-123 ioflupane): SPECT imaging of DAT
• F-18 FECNT: PET imaging of DAT

Key Publications

Ziebell M, et al. (2015). DaTscan in Parkinson's disease. Acta Neurol Scand.[@ziebell2015]

Background

The study of Dat Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

The Dopamine Transporter (DAT/SLC6A3) has characterized expression patterns in the brain:

• [Allen Human Brain Atlas - SLC6A3 Expression](https://human.brain-map.org/microarray/search/show?search_term=SLC6A3): Gene expression data across brain regions
• [Allen Mouse Brain Atlas - Slc6a3](https://mouse.brain-map.org/gene/show?gene_id=794): Mouse brain expression pattern
• [BrainSpan - Developmental Transcriptome](https://brainspan.org/static/html/download.html): Developmental expression patterns for SLC6A3

See Also

• SLC6A3 Gene
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Pathway](/mechanisms/dopamine-pathway)
• [VMAT2 Protein](/proteins/vmat2-protein)

External Links

• [UniProt: Q01959](https://www.uniprot.org/uniprot/Q01959)
• [PDB: 4MDS](https://www.rcsb.org/structure/4MDS)

DAT Imaging in Clinical Practice

DaTscan (I-123 Ioflupane)

DaTscan is an FDA-approved SPECT imaging agent used to visualize dopamine transporter binding in the striatum. The radiotracer I-123 ioflupane binds to DAT with high affinity, allowing visualization of presynaptic dopaminergic terminals. This imaging technique is clinically indicated for distinguishing Parkinson's disease and related disorders from essential tremor and other non-parkinsonian conditions. Reduced DAT binding in the caudate and putamen indicates dopaminergic neuron degeneration, which is characteristic of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.

PET Tracers

While DaTscan uses SPECT, PET tracers such as CFT (WIN 35,428) and other DAT ligands offer higher resolution imaging. These tracers are primarily used in research settings but may become more widely available as they offer improved quantification of dopaminergic terminal density. PET imaging can provide more precise measurements of DAT availability and can be combined with other tracers to assess postsynaptic dopamine receptors in the same imaging session.

Pharmacological Targeting

DAT Inhibitors

Several drugs target DAT for therapeutic purposes. Methylphenidate (Ritalin, Concerta) is a DAT blocker that increases extracellular dopamine and is widely used to treat ADHD. Cocaine is a potent DAT inhibitor that produces euphoria but has high abuse potential. Bupropion is an antidepressant that also inhibits DAT and is sometimes used as a smoking cessation aid.

Therapeutic Implications in PD

DAT imaging may help predict response to dopaminergic therapies in Parkinson's disease. Patients with preserved DAT binding generally respond better to levodopa and other dopamine replacement therapies. Additionally, DAT imaging can help identify patients who may develop levodopa-induced dyskinesias, as these complications are more common in patients with more severe dopaminergic terminal loss.

Regulation and Trafficking

Phosphorylation

DAT activity is regulated by multiple post-translational modifications. Protein kinase C (PKC) activation leads to DAT internalization and downregulation, reducing dopamine reuptake capacity. Amphetamine, a substrate releaser, causes DAT internalization through a different mechanism involving protein kinase activation and changes in intracellular distribution.

Glycosylation

DAT is heavily glycosylated in its extracellular loops, and glycosylation is essential for proper folding, trafficking, and function. Glycosylation defects can lead to protein misfolding and degradation. The glycosylation pattern may also affect DAT recognition by antibodies and other binding proteins.

Genetics

SLC6A3 Variants

The SLC6A3 gene has several polymorphisms that affect DAT expression and function. The 40-base pair variable number tandem repeat (VNTR) in the 3' untranslated region is the most studied, with 10-repeat alleles associated with higher DAT expression than 9-repeat alleles. These variants have been implicated in ADHD susceptibility, Parkinson's disease risk, and response to psychostimulant medications.

Parkinson's Disease Risk

While DAT variants are not major risk factors for sporadic Parkinson's disease, they may modify age of onset or disease severity. Some studies suggest that certain DAT haplotypes are associated with earlier onset Parkinson's disease, though results have been inconsistent across populations.

Brain Atlas Resources

The Dopamine Transporter (DAT/SLC6A3) has characterized expression patterns in the brain:

• [Allen Human Brain Atlas - SLC6A3 Expression](https://human.brain-map.org/microarray/search/show?search_term=SLC6A3): Gene expression data across brain regions
• [Allen Mouse Brain Atlas - Slc6a3](https://mouse.brain-map.org/gene/show?gene_id=794): Mouse brain expression pattern
• [BrainSpan - Developmental Transcriptome](https://brainspan.org/static/html/download.html): Developmental expression patterns for SLC6A3

References

[@zetterstrm2021]: Zetterström T, et al. Dopamine transporter imaging in Parkinson's disease. Mov Disord. 2021.
[@varrone2012]: Varrone A, Halldin C. Molecular imaging of dopamine transporters. J Neural Transm. 2012.
[@shin2020]: Shin NJ, et al. Structure of the human dopamine transporter in substrate-bound and inhibitor-bound states. Nature. 2020.

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3
• [Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling](/hypothesis/h-seaad-v4-29e81bbc) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: SLC16A1

Related Analyses:

• [Cell type vulnerability in Alzheimer&#x27;s Disease (SEA-AD data)](/analysis/SDA-2026-04-02-gap-seaad-20260402025452) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;
• [Cell type vulnerability in Alzheimer&#x27;s Disease (SEA-AD data - v2)](/analysis/SDA-2026-04-02-gap-seaad-v2-20260402032945) &#x1f504;